Novel Drugs in the Oncology Pipeline for 2H 2026

IPD Analytics has released a new report: "Novel Drugs in the Oncology Pipeline for 2H 2026."

Following a relatively limited first half of the year, the 2H 2026 oncology pipeline is notably more robust, featuring multiple novel agents anticipated across solid tumors and hematologic malignancies. The pipeline includes first-in-class and potentially best-in-class therapies spanning targeted treatments, antibody-drug conjugates (ADCs), radiopharmaceuticals, and cellular therapies.

Several pipeline candidates are pursuing biomarker-defined or niche oncology populations, reflecting the continued shift toward precision oncology and increasingly individualized treatment approaches. Others carry broader commercial opportunities, meaning market uptake and budget impact are expected to vary substantially across products and indications.

IPD Analytics projects that launch pricing for many of these agents will command a significant premium. Payers should anticipate growing budget pressure as novel therapies enter the market and clinical adoption expands across eligible patient populations.

Content on this site is proprietary to IPD Analytics. This sample is not for distribution. By receiving it, you agree to refrain from any unauthorized use, including uploading or inputting it into AI tools or large language models (LLMs) for training or any other purpose. This is strictly prohibited.